There's nothing like a pandemic to bring every biotech hopeful out of the shadows. No matter what they started off selling, everyone wants an antiviral angle these days. And in their haste to spruik their relevance to investors, many seem to be tripping over their own feet. Or the ASX's listing rules.

Medicinal cannabis producer MGC Pharmaceuticals, for one, can't decide whether its pot treatments have the potential to do coronavirus patients any good.